Spironolactone, a Classic Potassium-Sparing Diuretic, Reduces Survivin Expression and Chemosensitizes Cancer Cells to Non-DNA-Damaging Anticancer Drugs
出版年份 2019 全文链接
标题
Spironolactone, a Classic Potassium-Sparing Diuretic, Reduces Survivin Expression and Chemosensitizes Cancer Cells to Non-DNA-Damaging Anticancer Drugs
作者
关键词
-
出版物
Cancers
Volume 11, Issue 10, Pages 1550
出版商
MDPI AG
发表日期
2019-10-15
DOI
10.3390/cancers11101550
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Cancer statistics, 2019
- (2019) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Spironolactone inhibits the growth of cancer stem cells by impairing DNA damage response
- (2019) Ayala Gold et al. ONCOGENE
- Novel Third-Generation EGFR Tyrosine Kinase Inhibitors and Strategies to Overcome Therapeutic Resistance in Lung Cancer
- (2019) Ayesha Murtuza et al. CANCER RESEARCH
- Brexpiprazole, a Serotonin-Dopamine Activity Modulator, Can Sensitize Glioma Stem Cells to Osimertinib, a Third-Generation EGFR-TKI, via Survivin Reduction
- (2019) Shuhei Suzuki et al. Cancers
- Brexpiprazole Reduces Survivin and Reverses EGFR Tyrosine Kinase Inhibitor Resistance in Lung and Pancreatic Cancer
- (2019) TOMOMI SANOMACHI et al. ANTICANCER RESEARCH
- Long noncoding RNA LNC473 inhibits the ubiquitination of survivin via association with USP9X and enhances cell proliferation and invasion in hepatocellular carcinoma cells
- (2018) Hui Chen et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer
- (2018) Jean-Charles Soria et al. NEW ENGLAND JOURNAL OF MEDICINE
- Review of Drug Repositioning Approaches and Resources
- (2018) Hanqing Xue et al. International Journal of Biological Sciences
- Involvement of GLUT1-mediated glucose transport and metabolism in gefitinib resistance of non-small-cell lung cancer cells
- (2018) Shuhei Suzuki et al. Oncotarget
- 30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Mineralocorticoid receptor antagonists: 60 years of research and development
- (2017) Peter Kolkhof et al. JOURNAL OF ENDOCRINOLOGY
- Emerging functions of the EGFR in cancer
- (2017) Sara Sigismund et al. Molecular Oncology
- Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
- (2017) Tony S. Mok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Repositioning CEP-1347, a chemical agent originally developed for the treatment of Parkinson’s disease, as an anti-cancer stem cell drug
- (2017) Masashi Okada et al. Oncotarget
- Antitumor activity of gemcitabine against high-grade meningioma in vitro and in vivo
- (2017) Hiroyuki Takeda et al. Oncotarget
- The molecular mechanisms of chemoresistance in cancers
- (2017) Hua-Chuan Zheng Oncotarget
- Aripiprazole, an Antipsychotic and Partial Dopamine Agonist, Inhibits Cancer Stem Cells and Reverses Chemoresistance
- (2016) SHUHEI SUZUKI et al. ANTICANCER RESEARCH
- Pharmacokinetics and pharmacogenetics of Gemcitabine as a mainstay in adult and pediatric oncology: an EORTC-PAMM perspective
- (2016) Joseph Ciccolini et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- The cancer stem-cell signaling network and resistance to therapy
- (2016) A. Carnero et al. CANCER TREATMENT REVIEWS
- Cancer chemoresistance; biochemical and molecular aspects: a brief overview
- (2016) Saeed Kachalaki et al. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
- Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study
- (2016) James C Yao et al. LANCET
- Differences in reproductive toxicology between alopecia drugs: an analysis on adverse events among female and male cases
- (2016) Min Wu et al. Oncotarget
- Critical Care Management of Cerebral Edema in Brain Tumors
- (2016) Yoshua Esquenazi et al. JOURNAL OF INTENSIVE CARE MEDICINE
- Drug repositioning and repurposing: terminology and definitions in literature
- (2015) Joris Langedijk et al. DRUG DISCOVERY TODAY
- The Proapoptotic F-box Protein Fbxl7 Regulates Mitochondrial Function by Mediating the Ubiquitylation and Proteasomal Degradation of Survivin
- (2015) Yuan Liu et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer
- (2015) Pasi A. Jänne et al. NEW ENGLAND JOURNAL OF MEDICINE
- Incidence and risk of hypertension with bevacizumab in non-small-cell lung cancer patients: a meta-analysis of randomized controlled trials
- (2015) Yunliang Zheng et al. Drug Design Development and Therapy
- JNK suppression of chemotherapeutic agents-induced ROS confers chemoresistance on pancreatic cancer stem cells
- (2015) Shuhei Suzuki et al. Oncotarget
- A Small Molecule Screen Identifies an Inhibitor of DNA Repair Inducing the Degradation of TFIIH and the Chemosensitization of Tumor Cells to Platinum
- (2014) Sergey Alekseev et al. CHEMISTRY & BIOLOGY
- Gemcitabine: Metabolism and molecular mechanisms of action, sensitivity and chemoresistance in pancreatic cancer
- (2014) Lucas de Sousa Cavalcante et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- CUL9 Mediates the Functions of the 3M Complex and Ubiquitylates Survivin to Maintain Genome Integrity
- (2014) Zhijun Li et al. MOLECULAR CELL
- A high-throughput chemical screen with FDA approved drugs reveals that the antihypertensive drug Spironolactone impairs cancer cell survival by inhibiting homology directed repair
- (2014) Or David Shahar et al. NUCLEIC ACIDS RESEARCH
- Drug Resistance in Cancer: An Overview
- (2014) Genevieve Housman et al. Cancers
- Risk of hypertension with regorafenib in cancer patients: a systematic review and meta-analysis
- (2013) Zexing Wang et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Randomized phase III trial of gemcitabine and cisplatin vs. gemcitabine alone in patients with advanced non-small cell lung cancer and a performance status of 2: The CAPPA-2 study
- (2013) Alessandro Morabito et al. LUNG CANCER
- Specific role of JNK in the maintenance of the tumor-initiating capacity of A549 human non-small cell lung cancer cells
- (2013) MASASHI OKADA et al. ONCOLOGY REPORTS
- Gemcitabine Plus Erlotinib for Advanced Pancreatic Cancer: A Systematic Review with Meta-Analysis
- (2013) Zu-Yao Yang et al. PLoS One
- RTOG 0211: A Phase 1/2 Study of Radiation Therapy With Concurrent Gefitinib for Newly Diagnosed Glioblastoma Patients
- (2012) Arnab Chakravarti et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Targeting JNK for therapeutic depletion of stem-like glioblastoma cells
- (2012) Ken-ichiro Matsuda et al. Scientific Reports
- Overcoming Erlotinib Resistance in EGFR Mutation-Positive Non-Small Cell Lung Cancer Cells by Targeting Survivin
- (2011) K. Okamoto et al. MOLECULAR CANCER THERAPEUTICS
- Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
- (2011) José Baselga et al. NEW ENGLAND JOURNAL OF MEDICINE
- Role of Survivin in EGFR Inhibitor-Induced Apoptosis in Non-Small Cell Lung Cancers Positive for EGFR Mutations
- (2010) K. Okamoto et al. CANCER RESEARCH
- Phase II study of erlotinib plus gemcitabine in Japanese patients with unresectable pancreatic cancer
- (2010) Takuji Okusaka et al. CANCER SCIENCE
- A New Mode of Mineralocorticoid Receptor Antagonism by a Potent and Selective Nonsteroidal Molecule
- (2010) Jérôme Fagart et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034
- (2009) Martin J. van den Bent et al. JOURNAL OF CLINICAL ONCOLOGY
- Gemcitabine Resistance in Pancreatic Cancer: Picking the Key Players
- (2008) M. P. Kim et al. CLINICAL CANCER RESEARCH
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
- (2008) Robert J Motzer et al. LANCET
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More